Status | Study |
Completed |
Study Name: TKI258 for Metastatic Inflammatory Breast Cancer Patients Condition: Breast Cancer Date: 2010-12-15 Interventions: Drug: Dovitinib 500 mg by mouth for 5 consecutive days, followed by a 2-day rest period (5 days on/2 day |
Recruiting |
Study Name: MIRNA Profiling of Breast Cancer in Patients Undergoing Neoadjuvant or Adjuvant Treatment for Locally Advanced & Inflammatory Breast Cancer Condition: Breast Cancer Date: 2010-10-27 |
Active, not recruiting |
Study Name: Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer Condition: Breast Cancer Date: 2009-12-17 Interventions: Drug: Panitumumab 2.5 mg/kg IV |
Active, not recruiting |
Study Name: Efficacy and Tolerance Study of Bevacizumab in Her2- Inflammatory Breast Cancer Patients Condition: Breast Cancer Date: 2009-01-09 Interventions: Biological: bevacizumab During |
Recruiting |
Study Name: Case-Control Study of Inflammatory Breast Cancer in North Africa Condition: Inflammatory Breast Cancer Date: 2008-11-18 |
Terminated |
Study Name: Phase II Neoadjuvant in Inflammatory Breast Cancer Condition: Breast Cancer Date: 2008-09-19 Interventions: Drug: Lapatinib 1000 mg taken |
Completed |
Study Name: Inflammatory Breast Cancer, Tumor Markers, and Factors Associated With Angiogenesis Condition: Breast Neoplasms Date: 2008-03-27 |
Recruiting |
Study Name: Inflammatory Breast Cancer (IBC) Registry Condition: Breast Cancer Date: 2007-05-18 Interventions: Other: Interview Personal Inte |
Completed |
Study Name: Pilot Study of Inflammatory Breast Cancer in Egypt and Tunisia Condition: Inflammatory Breast Cancer Date: 2006-06-23 |
Completed |
Study Name: Establishing an Inflammatory Breast Cancer Registry Condition: Inflammatory Breast Cancer Date: 2006-06-19 |